SCHEMBL6294971

SCHEMBL6294971

CC(=O)SCC(CCc1ccccc1)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 1/20 0.50
MME P08473 2/20 0.49
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ABCC3 O15438 1/20 0.46
NR1I2 O75469 1/20 0.46
ABCB11 O95342 1/20 0.46
NR3C1 P04150 1/20 0.46
RARG P13631 1/20 0.46
CNR1 P21554 1/20 0.46
OPRK1 P41145 1/20 0.46
NR1H2 P55055 1/20 0.46
PPARA Q07869 1/20 0.46
NR1H3 Q13133 1/20 0.46
NR1I3 Q14994 1/20 0.46
ALDH1A1 P00352 1/20 0.44
GRIK1 P39086 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7429430 0.91 GRIK1 (0.56) CPB2MMECYP1A2CYP3A4CYP2D6
SCHEMBL8167065 0.89 CPB2 (0.57) CPB2MMECYP1A2CYP3A4CYP2D6
SCHEMBL8168663 0.88 CPB2 (0.60) CPB2MMECYP1A2CYP3A4CYP2D6
SCHEMBL7439894 0.86 TAAR1 (0.44) CPB2MMECYP1A2CYP3A4CYP2D6
SCHEMBL8462910 0.84 ACE (0.43) ACE
SCHEMBL7396931 0.84 LDHA (0.49) CPB2ALDH1A1
SCHEMBL838961 0.83 CYP1A2 (0.63) CPB2MMECYP1A2CYP3A4CYP2D6
SCHEMBL6154521 0.83 CYP1A2 (0.63) CPB2MMECYP1A2CYP3A4CYP2D6
SCHEMBL838962 0.83 CYP1A2 (0.63) CPB2MMECYP1A2CYP3A4CYP2D6
SCHEMBL6576344 0.83 CYP1A2 (0.44) CYP1A2GRIK1TSHRLAP3ERAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6864383-B2 Potassium channel moderators MERCK & CO., INC. (US) 2005-03-08 US disclosed
US-20040054213-A1 Using potassium channel moderators MERCK SHARP & DOHME CORP. 2004-03-18 US disclosed
EP-1358153-A1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION Merck & Co., Inc. (US) 2003-11-05 EP disclosed
WO-2002060863-A1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO., INC. (US) 2002-08-08 WO disclosed
US-6156774-A Beta-thiopropionyl-amino acid derivatives and their use as beta-lactamase inhibitors SMITHKLINE BEECHAM P.L.C. (GB) 2000-12-05 US disclosed
US-6048852-A BACTERICIDES SMITHKLINE BEECHAM P.L.C. (GB) 2000-04-11 US disclosed
US-6022885-A Pyrrolidine and thiazole derivatives with antibacterial and . metallo-.beta-lactamase inhibitory properties SMITHKLINE BEECHAM P.L.C. (GB) 2000-02-08 US disclosed
EP-0934262-A1 BETA-THIOPROPIONYL-AMINO ACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1999-08-11 EP disclosed
EP-0900197-A1 BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1999-03-10 EP disclosed
EP-0850230-A1 PYRROLIDINE AND THIAZOLE DERIVATIVES WITH ANTIBACTERIAL AND METALLO-BETA-LACTAMASE INHIBITORY PROPERTIES SMITHKLINE BEECHAM PLC (GB) 1998-07-01 EP disclosed
WO-1998017639-A1 BETA-THIOPROPIONYL-AMINO ACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1998-04-30 WO disclosed
WO-1997030027-A1 BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1997-08-21 WO disclosed
US-5629343-A INHIBITORS OF METALLOENDOPROTEINASES WHICH DEGRADE CARTILAGE MERCK & CO., INC. (US) 1997-05-13 US disclosed
WO-1997010225-A1 PYRROLIDINE AND THIAZOLE DERIVATIVES WITH ANTIBACTERIAL AND METALLO-BETA-LACTAMASE INHIBITORY PROPERTIES SMITHKLINE BEECHAM PLC (GB) 1997-03-20 WO disclosed
EP-0640594-A1 Hydantoin derivative as metalloprotease inhibitor FUJIREBIO INC. (JP) 1995-03-01 EP disclosed
WO-1994007481-A1 N-(MERCAPTOACYL)PEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE AGENTS MERCK & CO., INC. (US) 1994-04-14 WO disclosed
EP-0361365-A1 Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use E.R. SQUIBB & SONS, INC. (US) 1990-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040054213-A1 Using potassium channel moderators KCNN1, KCNN3, KCNJ2 CPB2 3797/4885MME 1362/4885CYP1A2 3146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.